Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: Report of a phase II trial

Bone Marrow Transplantation

Volumn 35, Issue 5, 2005, Pages 441-447

  Gupta, S ^a   Zhou, P ^a   Hassoun, H ^a   Kewalramani, T ^a   Reich, L ^a   Costello, S ^a   Drake, L ^a   Klimek, V ^a   Dhodapkar, M ^a,b   Teruya Feldstein, J ^a   Hedvat, C ^a   Kalakonda, N ^a   Fleisher, M ^a   Filippa, D ^a   Qin, J ^a   Nimer, S D ^a   Comenzo, R L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BACTEREMIA; BLEEDING; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CELL COMPOSITION; CELL COUNT; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FREQUENCY ANALYSIS; HOSPITALIZATION; HUMAN; HUMAN CELL; LEUKAPHERESIS; MALE; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT FAILURE; VIRUS INFECTION;

ADULT; AGE FACTORS; AGED; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKAPHERESIS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM CIRCULATING CELLS; NEUTROPENIA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 20144386351     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704779     Document Type: Article

References (46)

1. Durie BG, Kyle RA, Belch A et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379-398.
2. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488-493.
3. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
4. Goldschmidt H, Hegenbart U, Wallmeier M et al. Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy. Recent Results Cancer Res 1998; 144: 27-35.
5. Attal M, Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin N Am 1997; 11: 133-146.
6. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
7. Demirer T, Buckner CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-941.
8. Billadeau D, Quam L, Thomas W et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818-1824.
9. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-744.
10. Vescio RA, Han EJ, Schiller GJ et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 1996; 18 103-110.
11. McCann JC, Kanteti R, Shilepsky B et al. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 37-43.
12. Henry JM, Sykes PJ, Brisco MJ et al. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 1996; 92: 614-619.
13. Schiller G, Vescio R, Freytes C et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant 1998; 21: 113-115.
14. Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multi-center randomized controlled trial. J Clin Oncol 2001; 19: 3771-3779.
15. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
16. Gertz MA, Witzig TE, Pineda AA et al. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997; 19: 337-342.
17. Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-219.
18. Zhou P, Zhang Y, Martinez C et al. Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood 2003; 102: 477-479.
19. Zwicky CS, Maddocks AB, Andersen N, Gribben JG. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996; 88: 3314-3322.
20. Dreyfus F, Ribrag V, Leblond V et al. Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 1995; 15: 707-711.
21. McQuaker IG, Haynes AP, Anderson S et al. Engraftment and molecular monitoring of CD34 + peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. J Clin Oncol 1997; 15 2288-2295.
22. Cremer FW, Kiel K, Wallmeier M et al. A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol 1997; 8: 633-636.
23. Martinelli G, Terragna C, Lemoli RM et al. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34 stem cells. Haematologica 1999; 84: 397-404.
24. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med 1970; 283: 1121-1125.
25. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute leukemia associated with alkylating agents. Arch Intern Med 1975; 135: 185-192.
26. Arbuck SG, Ivy SP, Setser A et al. The Revised Common Toxicity Criteria: Version 2.0. CTEP Website. http://ctep.info.nih.gov.
27. Trotti A, Byhardt R, Stetz J et al. Common toxicity criteria: version 2.0, an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
28. Comenzo RL, Wally J, Kica G et al. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematology 1999; 106: 744-751.
29. Willems P, Verhagen O, Segeren C et al. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Blood 2000; 96: 63-70.
30. L germline gene use and plasma cell burden. Blood 2001; 98: 714-720.
31. Cremer FW, Kiel K, Wallmeier M et al. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol 1998; 26: 969-975.
32. Kiel K, Cremer FW, Ehrbrecht E et al. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow Transplantation 1998; 21: 1109-1115.
33. Cremer FW, Ehrbrecht E, Kiel K et al. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant 2000; 26: 851-858.
34. Comenzo RL, Michelle D, LeBlanc M et al. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion 1998; 38: 60-69.
35. Rosner B. Hypothesis Testing: Categorical Data. Fundamentals of Biostatistics. Wadsworth: Belmont, CA, 1994, pp 345-442.
36. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822-824.
37. Selby PJ, McElwain TJ, Nandi AC et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55-62.
38. Lokhorst HM, Sonneveld P, Wijermans PW et al. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Br J Haematol 1996; 92: 44-48.
39. Lokhorst HM, Sonneveld P, Cornelissen JJ et al. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant 1999; 23: 317 322.
40. Henon P, Donatini B, Eisenmann JC et al. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Bone Marrow Transplant 1995; 16: 19-25.
41. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23 1003-1006.
42. Carstanjen D, Regenfus M, Muller C, Salama A. Interleukin-6 is a major effector molecule of short-term G-CSF treatment inducing bone metabolism and an acute-phase response. Exp Hematol 2001; 29: 812-821.
43. Dhodapkar MV, Osman K, Teruya-Feldstein J et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immunity 2003; 23: 3:9-317.
44. Barlogie B, Shaughnessy JD, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
45. Morris CL, Siegel E, Barlogie B et al. Mobilization of CD34 + cells in elderly patients (≥70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413-423.
46. Gertz MA, Lacy MQ, Inwards DJ et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000; 26: 45-50.